Pi3k inhibitors

A method of treating a disease associated with mutations in PI3K, comprising administering to a subject in need thereof a compound having the following structure of Formula (II):

• or a stereoisomer of the compound, tautomer of the compound, or a salt thereof, wherein:
• R2 is C1-C3 alkyl;
• R3 is C1-C3 alkyl;
• R5 and R6 are, each independently, hydrogen or C1-C3 alkyl;
• R4 is 3-12 membered heterocyclyl or 5-10 membered heteroaryl, wherein the 3-12 membered heterocyclyl or 5-10 membered heteroaryl is optionally substituted with C1-C6 alkyl, C1-C6 haloalkyl, —O-phenyl, phenyl, or 5-10 membered heteroaryl, wherein the —O-phenyl, phenyl, or 5-10 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, halo, —CN, and C3-C7 cycloalkyl;
• R8 is C1-C4 alkyl;
• and
• each RA is independently hydrogen or halo.